ReviewRNA (New York, N.Y.)2016
Cracking the epitranscriptome.
Review in RNA (New York, N.Y.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 88 citations in OpenAlex.
- METTL3 abrogation promotes glioma progression through regulating the ISG15-FASN axis-mediated lipid metabolism in macrophages.Nature communications · 2026Article
- Innate Immune Surveillance and Recognition of Epigenetic Marks.Epigenomes · 2025Review
- Small Nucleolar RNAs: Biological Functions and Diseases.MedComm · 2025Review
- The RMaP challenge of predicting RNA modifications by nanopore sequencing.Communications chemistry · 2025Article
- Exploring the methyl-verse: Dynamic interplay of epigenome and m6A epitranscriptome.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- RNA Pol II-dependent transcription efficiency fine-tunes A-to-I editing levels.Genome research · 2024Article
- Current progress in strategies to profile transcriptomic mFrontiers in cell and developmental biology · 2024Review
- Simultaneous RNA and DNA Adductomics Using Single Data-Independent Acquisition Mass Spectrometry Analysis.Chemical research in toxicology · 2023Article
- The importance of pseudouridylation: human disorders related to the fifth nucleoside.Biologia futura · 2023Review
- Loss of the m6A methyltransferase METTL3 in monocyte-derived macrophages ameliorates Alzheimer's disease pathology in mice.PLoS biology · 2023Article
- lncRNA ZNRD1-AS1 promotes malignant lung cell proliferation, migration, and angiogenesis via the miR-942/TNS1 axis and is positively regulated by the mMolecular cancer · 2022Article
- Reduction of Methyltransferase-like 3-Mediated RNA N6-Methyladenosine Exacerbates the Development of Psoriasis Vulgaris in Imiquimod-Induced Psoriasis-like Mouse Model.International journal of molecular sciences · 2022Article
- Chemical modifications to mRNA nucleobases impact translation elongation and termination.Biophysical chemistry · 2022Review
- A systematic dissection of determinants and consequences of snoRNA-guided pseudouridylation of human mRNA.Nucleic acids research · 2022Article
- The RNA methyltransferase METTL8 installs mNature communications · 2022Article
- The role of RNA modification in hepatocellular carcinoma.Frontiers in pharmacology · 2022Review
- Epitranscriptomics of cardiovascular diseases (Review).International journal of molecular medicine · 2022Review
- The human pseudouridine synthase PUS7 recognizes RNA with an extended multi-domain binding surface.Nucleic acids research · 2021Article
- Identification of the function and mechanism of m6A reader IGF2BP2 in Alzheimer's disease.Aging · 2021Article
- Mechanism of noncoding RNA-associated NMolecular cell · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over 100 distinct chemical modifications can be catalyzed on RNA post-synthesis, potentially serving as a post-transcriptional regulatory layer of gene expression. This review focuses on recent advances, knowledge gaps, and challenges pertaining to N6-methyladenosine (m6A), an abundant modification of mRNA for which substantial progress has been made in recent years. The discussed aspects are also very relevant for a wide range of additional modifications on mRNA collectively coined the epitranscriptome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.